Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX

Nisa Investment Advisors LLC reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 80.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,201 shares of the company’s stock after selling 21,945 shares during the period. Nisa Investment Advisors LLC’s holdings in Neurocrine Biosciences were worth $738,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after purchasing an additional 468,405 shares during the period. AQR Capital Management LLC boosted its holdings in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after purchasing an additional 1,263,633 shares in the last quarter. Deerfield Management Company L.P. grew its stake in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock valued at $166,258,000 after purchasing an additional 16,543 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Neurocrine Biosciences by 3.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 710,122 shares of the company’s stock valued at $99,686,000 after purchasing an additional 25,683 shares during the period. Finally, Armistice Capital LLC raised its holdings in shares of Neurocrine Biosciences by 3.1% in the 3rd quarter. Armistice Capital LLC now owns 697,022 shares of the company’s stock worth $97,848,000 after buying an additional 20,998 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 36,400 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $131.60 on Friday. The stock’s 50 day simple moving average is $131.56 and its 200 day simple moving average is $139.12. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $160.18. The firm has a market cap of $13.21 billion, a PE ratio of 28.24, a price-to-earnings-growth ratio of 0.69 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). The business had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The company’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.69 EPS. As a group, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. Truist Financial decreased their price target on Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. HC Wainwright dropped their price objective on Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Wells Fargo & Company cut their price objective on Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Zacks Research downgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. Finally, JPMorgan Chase & Co. upped their target price on shares of Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $175.10.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.